This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Production has already begun and will continue to ramp up on several new programs before the first of the year. The site focuses on the industrialization and production of inhalers, insulin pens, transfer devices and syringes.
The expansion includes 12,900 square feet (1,200 square meters) of Class 8 clean room manufacturing and assembly, and has space for the additional expansion for molding machines and assembly. New, state-‐of-‐the art, high-‐speed automation lines enable the ramp up of multi-‐component, complex drug delivery devices from prototype to high-‐speed automated 24/7 mass production under competitive cost-‐structure. Total Kontiolahti numbers now include, multiple high-‐speed, fully automated assembly lines; fully automated printing lines; and several semi-‐automated lines.
Since 1990, the Kontiolahti team has been serving the pharmaceutical industry with strong engineering resources, along with injection molding and high-‐speed automation expertise to support complex, high volume programs. The in-‐house tooling area, coupled with experts on the pre-‐production team, plays a vital role in the product development and industrialization of the demanding drug delivery device projects.
Commenting on this plant expansion, Matt Jennings, President and CEO of Phillips-‐Medisize Corporation stated, “The ISO 13485 multi-‐site QMS certified expansion brings our medical manufacturing square footage to over 1 million square feet (92,900 square meters), with 270,000 square feet (25,000 square meters) of clean room. This, coupled with extensive in-‐house tooling, state-‐of-‐the-‐art metrology, high volume automated assembly capabilities, innovative technologies, and creative people, upholds our mission to provide the highest level of satisfaction to our customers.
